RxDoctor Payments Data

Charles Danish, DO

Internal Medicine · Henderson, NVNPI 1790149078

Payments from drug & device makers

$538in general payments, 2019–2025

Across 14 payments — averaging $38.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$173
  • E.r. Squibb & Sons, L.L.C.$122
  • Gilead$119
  • Pfizer$52
  • Abiomed$32
  • Fisher Scientific Company L.L.C.$20
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$538100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic1$173
E.r. Squibb & Sons, L.L.C.1$122
Gilead6$119
Pfizer2$52
Abiomed2$32
Fisher Scientific Company L.L.C.1$20
Novo Nordisk1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$538 in reported general payments places this provider in the 60th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$224,913
Medicare patients
522
Services billed
2,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$33,667
Rosuvastatin Calcium61$625
Albuterol Sulfate HfaAlbuterol Sulfate27$554
Atorvastatin Calcium64$340
Cefdinir30$269
Pantoprazole Sodium40$243
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$189
Amlodipine Besylate64$162
Carvedilol41$155
ClopidogrelClopidogrel Bisulfate25$144
Prednisone29$126
Losartan Potassium25$119
Famotidine16$105
Spironolactone22$104
Doxycycline Hyclate15$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$33,66756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →